Clinuvel Pharmaceuticals Limited (CUVL) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Clinuvel Pharmaceuticals Limited (CUVL) advanced +1.58% to $5.15, trading at 7% of its 52-week range ($4.88 – $8.92). Solid 81% profit margin (81% profit margin), mixed timing at 11x P/E—hold if owned, no rush to chase.
Wall Street’s favorite high growth plays have slipped into their worst slump since 2010, and that pullback has many investors looking beyond crowded AI trades. Australian biotech stocks offer a different type of potentia
Recent weakness in US technology shares as investors question heavy AI spending has pushed some capital away from crowded global themes and towards areas tied to real science solving real problems. That shift puts Austra
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +5.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CUVL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CUVL. Explore sector supply chains on /butterfly.
Across 485 tracked Industrials securities in the Roarable RQD universe, Clinuvel Pharmaceuticals Limited (CUVL) ranks #108 by composite RQD confidence (66/100, grade C+) and #335 by equity capitalization ($257.8M). Within this direct 5-issuer industry benchmark cohort, CUVL leads on earnings valuation at 11.1x trailing P/E, while FERG leads on capital efficiency and profitability with 22.2% ROIC and 30.7% gross margin. FERG currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with CUVL at 66/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CUVL
ACTIVE
Clinuvel Pharmaceuticals Limited | C+ | 66/100 | 11.1x | 81.2% | — | +1.58% | $257.8M | Benchmark Subject |
| CDTG CDT Environmental Technology Investment Holdings Limited | E | 26/100 | — | 41.5% | -30.1% | -7.84% | $2.8M | /cdtg-vs-cuvl → |
| DXST Decent Holding Inc (Class A) | D | 47/100 | — | 26.2% | — | +2.68% | $2.4M | /dxst-vs-cuvl → |
| FERG Ferguson Enterprises Inc. | C+ | 69/100 | 25.1x | 30.7% | 22.2% | +4.21% | $46.52B | /ferg-vs-cuvl → |
| NKLR Terra Innovatum Global N.V. | E | 32/100 | — | — | -35.0% | -2.51% | $257.5M | /nklr-vs-cuvl → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Clinuvel Pharmaceuticals Limited (CUVL) reported GAAP revenue of $61.1M (+5.5% vs. FY2024 revenue of $57.9M ) , GAAP net income of $23.1M, operating cash flow of $27.3M, and free cash flow of $27.1M (+34.9% YoY). On the balance sheet, CUVL closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $61.1M | $23.1M | $27.3M | $27.1M | — | — |
| FY2024 (FY) | 2024-06-30 | $57.9M | $23.3M | $23.8M | $20.1M | — | — |
As of 2026-11-01, Clinuvel Pharmaceuticals Limited (NASDAQ: CUVL) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $5.15 (+1.58% 1D, market cap $257.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 485 tracked Industrials issuers, CUVL ranks #108 in composite RQD confidence.
Within the Industrials sector (Miscellaneous), CUVL carries a Roarable C+ (66/100 RQD), trailing P/E of 11.1x, gross margin of 81.2%, and ROIC of —. By comparison, CDTG (CDT Environmental Technology Investment Holdings Limited) holds a E grade (26/100 RQD, P/E N/A, ROIC -30.1%, cap $2.8M) and DXST (Decent Holding Inc (Class A)) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $2.4M). Among the 5-stock peer group, CUVL leads on earnings multiple (11.1x) while FERG leads on capital efficiency (22.2% ROIC).
Per CUVL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001290877), Clinuvel Pharmaceuticals Limited generated $61.1M in revenue (+5.5% YoY), $23.1M in net income, and $27.1M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (81% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
CUVL last traded at $5.15 (+1.58% on volume of 8,165 shares), positioning the stock -11.66% below its 50-day simple moving average ($5.83) and -24.15% below its 200-day simple moving average ($6.79). Across its 52-week range of $4.88 to $8.92, CUVL sits at the 6.7% percentile with a 14-day RSI of 37.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.5% ($4.71 to $5.59).
Why CUVL Stock advanced +1.58% Today — RQD Quant Desk Flash. Solid 81% profit margin (81% profit margin), mixed timing at 11x P/E—hold if owned, no rush to chase.